VistaGen Therapeutics, Inc.
VTGN
$0.70
$0.0913.85%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/17/2026
-
Simply Wall St
6/15/2026
-
The Cerbat Gem
6/15/2026
-
Business Wire
6/9/2026
-
TipRanks
6/9/2026
-
GuruFocus
6/9/2026
-
Business Wire
6/3/2026
-
Zacks Investment Research
6/1/2026
-
GuruFocus
6/1/2026
-
PR Newswire
5/28/2026
-
Zacks Investment Research
5/27/2026
-
Business Wire
5/20/2026
-
Zacks Investment Research
5/19/2026
-
Insider Monkey
5/18/2026
-
Zacks Investment Research
5/18/2026
-
Zacks Investment Research
5/18/2026
-
Insider Monkey
5/14/2026
-
Business Wire
5/12/2026
-
Business Wire
5/8/2026
-
TipRanks Financial Blog
5/8/2026
-
TipRanks Financial Blog
5/8/2026
-
Business Wire
5/1/2026
-
Ticker Report
4/29/2026
-
Globe Newswire
4/28/2026
-
PR Newswire
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, June 15, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 577 3600
Address
343 Allerton Avenue
South San Francisco, CA 94080
South San Francisco, CA 94080
Country
Year Founded
Business Description
Sector
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The...
more